|
|
|
|
Phase III Study Showed Lucentis Improved Vision In Patients With Branch Retinal Vein Occlusion
Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
Phase-III study shows Lucentis improves vision in branch retinal vein occlusion
Roche announced that the phase-III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular...
|
|
|
Regulation of vascular endothelial growth factor and pigment epithelium-derived factor in rat retinal explants
To explore whether retinal acidification independently regulates the production of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) and whether the regulation is related to oxidative stress.Methods...
|
|
|
Jul 2, 2009
-- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Study Showed Early and Sustained Improvement in Vision Through Six Months -- ) SOUTH SAN FRANCISCO, Calif., Jul 02, 2009 (BUSINESS WIRE) -- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis(R) (ranibizumab...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
-- Study Showed Early and Sustained Improvement in Vision Through Six Months -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Companies mentioned in this article: Genentech, Inc.SOUTH SAN FRANCISCO, Calif. -- (BUSINESSWIRE) -- Genentech, Inc. announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
BusinessWire - Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis(R) (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis(R) (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in...
|
|
|
Genentech drug does well in blindness test
Genentech Inc.said a Phase III study of Lucentis in patients with swelling of the eye caused by branch retinal vein occlusion a common cause of blindness showed that the drug improved vision. The San Francisco-based, wholly owned...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
-- BRAVO evaluated the safety and efficacy of six monthly injections of Lucentis compared to monthly sham injections.The two doses of Lucentis studied showed a statistically significant improvement in best-corrected visual acuity (the...
|
|
|
Genentech drug does well in blindness test
Genentech Inc.said a Phase III study of Lucentis in patients with swelling of the eye caused by branch retinal vein occlusion a common cause of blindness showed that the drug improved vision. The San Francisco-based, wholly owned...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
-- Study Showed Early and Sustained Improvement in Vision Through Six Months -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul 2, 2009 - Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab...
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
-- Study Showed Early and Sustained Improvement in Vision Through Six Months -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul 2, 2009 - Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab...
|
|
|
Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes
_ Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes.
|
|
|
Phase III Study Showed Lucentis Improved Vision in Patients with Branch R
Genentech, Inc.announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in...
|
|
|
Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases: Basic Research to Clinical Application
Location: Bethesda, MD USA Contact Info: Rhonda Williams Phone: 240/221-2908 Fax Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases: Basic Research to Clinical Application.
|
|
|
Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes
_ Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes.
|
|
|
Enalapril, Losartan May Have Retinal, but Not Renal, Benefits in Type 1 Diabetes
_ Enalapril, Losartan May Have Retinal, but Not Renal, Benefits in Type 1 Diabetes.
|
|
|
Enalapril, Losartan May Have Retinal, but Not Renal, Benefits in Type 1 Diabetes
_ Enalapril, Losartan May Have Retinal, but Not Renal, Benefits in Type 1 Diabetes.
|
|
|
Enalapril, Losartan May Have Retinal, but Not Renal, Benefits in Type 1 Diabetes
_ Enalapril, Losartan May Have Retinal, but Not Renal, Benefits in Type 1 Diabetes.
|
|
|
Alagille Syndrome Associated with Myelinated Retinal Nerve Fibers
_ Alagille Syndrome Associated with Myelinated Retinal Nerve Fibers.
|
|
|
AGTC And National Neurovision Research Institute Collaborate, Funding Research In Two Genetic Retinal Diseases
Applied Genetic Technologies Corporation (AGTC), a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that AGTC has entered into an agreement with the National Neurovision...
|
